Table 1 Correlations between IL-20 expression to various clinicopathological parameters.
From: Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma
Number | IL-20 Exp. | P-value | ||
---|---|---|---|---|
Low | High | |||
Sex | 0.135 | |||
Male | 84 | 39 | 45 | |
Female | 20 | 13 | 7 | |
Age (years) | 1.000 | |||
<60 | 48 | 24 | 24 | |
≧60 | 56 | 28 | 28 | |
Hepatitis | 0.529 | |||
HBV | 54 | 29 | 25 | |
HCV | 38 | 17 | 21 | |
Both | 4 | 1 | 3 | |
None | 8 | 5 | 3 | |
Pugh-Child’s Classification | 0.010* | |||
A | 85 | 45 | 40 | |
B | 6 | 0 | 6 | |
C | 3 | 0 | 3 | |
AFP | 0.292 | |||
<400 | 75 | 42 | 33 | |
≧400 | 23 | 10 | 13 | |
Tumor Multiplicity | 0.003* | |||
Solitary | 61 | 38 | 23 | |
Multiple | 43 | 14 | 29 | |
Differentiation | 0.003* | |||
Well/Moderately differentiated | 79 | 46 | 33 | |
Poorly differentiated | 25 | 6 | 19 | |
Primary Tumor (pT) | 0.002* | |||
pT1 | 42 | 27 | 15 | |
pT2 | 32 | 18 | 14 | |
pT3–4 | 30 | 7 | 23 | |
AJCC Stage | 0.002* | |||
Stage I | 40 | 26 | 14 | |
Stage II | 32 | 18 | 14 | |
Stage III-V | 32 | 8 | 24 | |
CLIP score | 0.001* | |||
0–1 | 63 | 37 | 26 | |
2–3 | 30 | 7 | 23 | |
Okuda stage | 0.003* | |||
I | 62 | 36 | 26 | |
II-III | 31 | 8 | 23 |